Like a myth, 12-month DAPT after ACS can only be passed on, at least until it is demystified. Have a look at this Frontiers paper just published in Circulation led by Marco Valgimigli

#Frontiers Exploring an evidenced based approach to duration of dual antiplatelet therapy following an #ACS Marco Valgimigli ahajournals.org/doi/full/10.11…

Bleeding risk prioritization after PCI: a Copernican revolution just published in EHJ Editor-in-Chief Marco Valgimigli doi.org/10.1093/eurhea…

Me, when someone is telling me why they don’t use intra-coronary imaging…

Less than a week for our first workshop entitled “Swiss Cardiovascular Updates - WAVE 1.0”. Join us for this update in the field of ACS. Please register for in presence and online participation➡️ eventi.eoc.ch/wave/ Marco Valgimigli Leonardo De Luca, MD, PhD, FACC, FESC

"Hepatic T1 mapping has emerged as a novel imaging biomarker of the cardio-hepatic axis in STEMI, being associated with RV involvement and increased NT-proBNP" doi.org/10.1093/ehjci/… Thanks to Anna Giulia Pavon for the leadership and to the whole Team! #whyCMR #CVimaging

Double trouble: antithrombotic tx in #HBR patients with #diabetes undergoing PCI. Our latest insights from #MASTERDAPT ⬇️

💡Swinging Pendulum Between Risks and Benefits of Antiplatelet Agents: our call for consistency of future guideline recommendations just published in Circulation Marco Valgimigli ahajournals.org/doi/full/10.11…

Our call for consistency of evidence interpretation and guidelines recommendations on antiplatelet tx Circulation

Must apply!

Should the default duration of #DAPT after PCI in ACS be 12 months? Our great debate just published in EHJ Editor-in-Chief Marco Valgimigli Robert Byrne Dr. Deepak L. Bhatt C. Michael Gibson MD Borja Ibanez Xavier Rosselló Ph.Gabriel Steg Gregg W. Stone MD doi.org/10.1093/eurhea…

Featured Article: PIM acting as a weak reversible inhibitor seems to compete for the same binding site as PAM on the P2Y12 receptor Marco Valgimigli Antonio Landi ahajrnls.org/4cROQav

Here are 10 reasons NOT to routinely pre-treat NSTE-ACS patients with P2Y12 inhibitors

Glad to be for my very first time to the ANMCO congress to tackle an increasingly recognized issue in practice: the decision-making process in elderly patients. Leonardo De Luca, MD, PhD, FACC, FESC Gianluca Campo Claudio Montalto

I was privileged to celebrate today @PCR the memory of Tiziana Zaro and dedicate her one sub-analysis of @masterdapt which we thought it was special and unique as she has been and will continue to be for us

Recurrent events after PCI in HBR patients #MASTERDAPT #euroPCR2025

Check out my latest article: Recurrent Events After PCI in High Bleeding Risk Patients: New Insights from the MASTER DAPT Trial linkedin.com/pulse/recurren… via LinkedIn

💡 In PCI patients who had discontinued DAPT, P2Y12 inhibitor monotherapy was associated with lower MACCE compared with aspirin, without an increased risk of bleeding. Read more in The BMJ 🔗 bmj.com/content/389/bm… Marco Valgimigli Daniele Giacoppo PCRonline 🫀 TCTMD theheartorg | Medscape

Radial access for PCI: the good, the better, and the ugly Marco Valgimigli ➡️doi.org/10.1093/eurhea… Our editorial on a recent study from the NCDR CathPCI registry Sunil V. Rao Robert W. Yeh doi.org/10.1093/eurhea…

Radial access for PCI: The good, the better, and the ugly. New trends from Europe and the US highlight the growing shift toward radial access, with promising outcomes in coronary procedures. A game-changer in PCI. Read more in #EHJ. doi.org/10.1093/eurhea… #cardiotwitter